ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $781 | -64.6% | 48,085 | -59.8% | 0.01% | -70.6% |
Q1 2024 | $2,209 | -61.7% | 119,492 | -56.8% | 0.02% | -69.1% |
Q3 2023 | $5,769 | +210.0% | 276,829 | +179.9% | 0.06% | +266.7% |
Q1 2023 | $1,861 | -75.0% | 98,890 | -78.8% | 0.02% | -86.1% |
Q4 2022 | $7,432 | -99.3% | 466,843 | +665.4% | 0.11% | +730.8% |
Q3 2022 | $998,000 | +58.2% | 60,997 | +36.2% | 0.01% | +62.5% |
Q2 2022 | $631,000 | -64.7% | 44,773 | -39.3% | 0.01% | -65.2% |
Q1 2022 | $1,786,000 | +142.7% | 73,761 | +144.3% | 0.02% | +187.5% |
Q2 2021 | $736,000 | +9.9% | 30,188 | +16.3% | 0.01% | -20.0% |
Q1 2021 | $670,000 | -77.4% | 25,959 | -53.3% | 0.01% | -65.5% |
Q4 2020 | $2,970,000 | +389.3% | 55,556 | +277.6% | 0.03% | +141.7% |
Q3 2020 | $607,000 | -91.1% | 14,712 | -89.6% | 0.01% | -93.2% |
Q2 2020 | $6,835,000 | +1864.1% | 141,006 | +1613.7% | 0.18% | +831.6% |
Q1 2020 | $348,000 | -82.6% | 8,228 | -82.4% | 0.02% | -50.0% |
Q4 2019 | $2,001,000 | – | 46,781 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |